Search Results - "Daamen, Carolin"

High rates of therapeutic changes in patients with psoriatic arthritis receiving treatment with disease-modifying antirheumatic drugs: A cross-sectional study by Behrens, Frank, Rech, Jürgen, Thaçi, Diamant, Zinke, Silke, Rothnie, Kieran J, (Oefner) Daamen, Carolin, Leipe, Jan

“…To characterize treatment patterns for patients with psoriatic arthritis (PsA) currently receiving any disease-modifying antirheumatic drug (DMARD). The S…”
Get full text

Short-, Mid-, and Long-Term Efficacy of Deucravacitinib Versus Biologics and Nonbiologics for Plaque Psoriasis: A Network Meta-Analysis by Armstrong, April W., Warren, Richard B., Zhong, Yichen, Zhuo, Joe, Cichewicz, Allie, Kadambi, Ananth, Junqueira, Daniela, Westley, Tracy, Kisa, Renata, Daamen, Carolin, Augustin, Matthias

“…Introduction Deucravacitinib, a newly approved oral medication for the treatment of patients with moderate to severe plaque psoriasis, demonstrated efficacy…”
Get full text

High rates of therapeutic changes in patients with psoriatic arthritis receiving treatment with disease-modifying antirheumatic drugs: A cross-sectional study by Behrens, Frank, Rech, Jürgen, Thaçi, Diamant, Zinke, Silke, Rothnie, Kieran J, Oefner Daamen, Carolin, Leipe, Jan

“…To characterize treatment patterns for patients with psoriatic arthritis (PsA) currently receiving any disease-modifying antirheumatic drug (DMARD). The…”
Get full text

Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in moderate to severe plaque psoriasis: 52-week efficacy by prior treatment in the phase 3 POETYK PSO-1 trial by Bagel, Jerry, Armstrong, April W., Warren, Richard B., Papp, Kim A., Thaçi, Diamant, Menter, Alan, Cather, Jennifer, Augustin, Matthias, Hippeli, Lauren, Daamen, Carolin, Griffiths, Christopher EM

“…Introduction: Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, is approved by the US FDA for the treatment of adults with…”
Get full text

Deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in moderate to severe plaque psoriasis: 52-week efficacy by prior treatment in the phase 3 POETYK PSO-1 trial by Bagel, Jerry, Armstrong, April, Warren, Richard, Papp, Kim, Thaçi, Diamant, Menter, Alan, Cather, Jennifer, Augustin, Matthias, Hippeli, Lauren, Daamen, Carolin, Griffiths, Christopher

Get full text

Indirect comparison of the short-, mid-, and long-term efficacy of treatments for moderate to severe plaque psoriasis: a systematic review and network meta-analysis by Armstrong, April W, Warren, Richard B, Zhong, Yichen, Zhuo, Joe, Cichewicz, Allie, Kadambi, Ananth, Junqueira, Daniel R, Westley, Tracy, Kisa, Renata, Daamen, Carolin, Augustin, Matthias

Get full text

Deucravacitinib in Plaque Psoriasis: 4-year Safety and Efficacy Results from the Phase 3 POETYK PSO-1, PSO-2, and LTE Trials by Armstrong, April W., Lebwohl, Mark, Warren, Richard B., Sofen, Howard, Morita, Akimichi, Imafuku, Shinichi, Ohtsuki, Mamitaro, Spelman, Lynda, Passeron, Thierry, Papp, Kim A., Colombo, Matthew J., Vaile, John, Vritzali, Eleni, Hoyt, Kim, Daamen, Carolin, Banerjee, Subhashis, Strober, Bruce, Thaçi, Diamant, Blauvelt, Andrew

“…Introduction: Deucravacitinib, an oral, selective, allosteric TYK2 inhibitor, is approved in multiple countries for treatment of adults with moderate to severe…”
Get full text

Deucravacitinib in Plaque Psoriasis: 4-Year Safety and Efficacy Results From the Phase 3 POETYK PSO-1, PSO-2, and LTE Trials by Armstrong, April W., Lebwohl, Mark, Warren, Richard B., Sofen, Howard, Morita, Akimchi, Imafuku, Shinichi, Ohtsuki, Mamitaro, Spelman, Lynda, Passeron, Thierry, Papp, Kim A., Colombo, Matthew J., Vaile, John, Vritzali, Eleni, Hoyt, Kim, Daamen, Carolin, Banerjee, Subhashis, Strober, Bruce, Thaçi, Diamant, Blauvelt, Andrew

“…Introduction: Deucravacitinib, an oral, selective, allosteric TYK2 inhibitor, is approved in the US, EU, and other countries for treatment of adults with…”
Get full text